TQ Quiz | Optimizing Glaucoma Care: Managing the Comorbidities (Detroit 2025)

"*" indicates required fields

This field is hidden when viewing the form

Date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event Date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event 90 days past date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event Date Difference (Hidden)

1. Which risk factor for primary open angle glaucoma development shows significant overlap with risk factors for other ocular pathologies?*

A - Age

B - Sex

C - Occupation

D - Diet

2. In a personalized approach to open angle glaucoma management, how should the frequency of visual field testing be determined?*

A - Based on the patient age only

B - Based on individualized risk of disease progression

C - Frequency of testing should be uniform for all patients

D - Based solely on IOP

3. Other than glaucoma, what is another cause of arcuate retinal nerve fiber layer defect?*

A - Cataract

B - Retinal ischemia

C - Macular neovascularization

D - Retinal tear

4. To reduce patient fatigue when managing multiple ophthalmic conditions, what strategy optimizes testing frequency?*

A - Stacking procedures on the same day when possible

B - Increasing the frequency of clinical visits

C - Duplicative testing

D - Isolated specialist consultations

5. What is the characteristic finding of retinal ischemic perivascular lesions (RIPLs) on OCT?*

A - Hyperreflective deposits in the outer retina

B - Thickening of the retinal nerve fiber layer

C - Focal atrophy of the inner nuclear layer and expansion of the outer nuclear layer

D - Increased thickness of the retinal pigment epithelium

6. In primary open angle glaucoma, what is the primary mechanism leading to visual field damage?*

A - Corneal thinning

B - Progressive ganglion cell axonal loss

C - Reduction in photoreceptor density

D - Increased choroidal blood flow

7. Which systemic condition increases the risk for development of primary open angle glaucoma?*

A - Asthma

B - Diabetes mellitus

C - Osteoarthritis

D - Primary hypothyroidism

8. How do benzalkonium chloride (BAK)-preserved topical ophthalmic medications impact the ocular surface?*

A - They improve tear film stability

B - They can disrupt goblet cells and meibomian glands

C - They increase eyelid laxity

D - They decrease tear film evaporation

9. How can systemic antihypertensive medications affect ocular perfusion in glaucoma patients?*

A - They increase intraocular pressure

B - They do not impact ocular perfusion

C - They may decrease ocular perfusion pressure

D - They improve ocular perfusion pressure

10. What is a potential mechanism for IOP rise immediately after intravitreal injections?*

A - Volume-related spike

B - Increased aqueous production

C - Reduced corneal endothelial function

D - Acute angle closure crisis

11. How often should dilated retinal examination be performed in highly myopic glaucoma patients?*

A - Based on risk, often annually or more frequently

B - Every 3-5 years

C - Only when symptomatic

D - Dilated retinal examinations are not necessary

12. Which of the following OCT-based biomarkers indicates higher risk of age-related macular degeneration progression?*

A - Hyperreflective foci

B - Retinal pigment epithelium thickness

C - Macular curvature index

D - Vitreous opacity density

13. Which topical ophthalmic IOP-lowering medication contains a nitric-oxide donating moiety?*

A - Latanoprostene bunod 0.024% (Vyzulta)

B - Netarsudil 0.02% (Rhopressa)

C - Dorzolamide 2%

D - Preservative-free latanoprost 0.005% (Iyuzeh)

14. How does the volume differ between FDA approved intravitreal injections for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) from that of anti-VEGF agents?*

A - The volume of GA treatments is larger

B - The volume of GA treatment is smaller

C - The volume of GA treatments is not relevant due to their route of administration

D - The volume of GA treatments is 0.05mL

15. How may vitreomacular traction affect OCT imaging in glaucoma?*

A - It may improve image quality

B - It may decrease axial resolution

C - It may lead to segmentation error

D - It has no effect on OCT imaging

16. Which of the following features is central to differentiating non-glaucomatous optic neuropathy from glaucomatous optic neuropathy*

A - Optic disc pallor

B - Visual field defect

C - Relative afferent pupillary defect

D - Statistically normal intraocular pressure

17. All of the following features are relevant to determining a target IOP, EXCEPT:*

A - Age

B - Disease severity

C - Peak, untreated IOP

D - Presence of dry eye disease

18. Which clinical scenario is an indication for trabeculectomy?*

A - Symptoms of dry eye disease with treatment on a single topical ophthalmic agent

B - Early cataract with moderate stage primary open angle glaucoma

C - Uncontrolled IOP despite maximally tolerated medical therapy

D - It has no effect on OCT imaging

19. Which of the following agents is preservative-free?*

A - Travatan Z (travoprost ophthalmic solution) 0.004%

B - Iyuzeh (latanoprost ophthalmic solution) 0.005%

C - Lumigan (bimatoprost ophthalmic solution) 0.01%

D - Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%

20. What does the SPEED questionnaire stand for in the context of evaluating dry eye disease symptoms?*

A - Standard Patient Evaluation of Eye Dryness

B - Symptom Profile for Eye Evaluation and Diagnosis

C - Special Patient Eye Examination and Detection

D - Scale for Painful Eye Examination and Dryness

Personal Information

Name*

First Last

Email*

Phone*

OE Tracker #

License #

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Payment Information

Promotional Code

Detroit 2025 - Optimizing Glaucoma Care: Managing the Comorbidities*

After 90 days, pricing will increase to $30.

Price:

Retake Discount

Price:

Promotional Discount

Price:

Credit Card*

This field is hidden when viewing the form

Course Information (HIDDEN)

This field is hidden when viewing the form

Course Name (HIDDEN)

This field is hidden when viewing the form

Retake Code (HIDDEN)

This field is hidden when viewing the form

Quiz URL (HIDDEN)

Do not include ending backslash (aka no .com/)

This field is hidden when viewing the form

CE Hours

TQ Quiz | Optimizing Glaucoma Care: Managing the Comorbidities (Detroit 2025)

Personal Information

Payment Information

Course Information (HIDDEN)

Submit a Comment Cancel reply

Upcoming Conferences

Case Challenges

Case Challenges

TQ Quiz | Optimizing Glaucoma Care: Managing the Comorbidities (Detroit 2025)

Personal Information

Payment Information

Course Information (HIDDEN)

Submit a Comment Cancel reply

Upcoming Conferences

Case Challenges

Case Challenges

Subscribe For Event Updates